Daniel Gordon Kirby's most recent trade in Iovance Biotherapeutics Inc was a trade of 30,000 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 05 Jun 2025 | 30,000 | 30,000 (0%) | 0% | 1.8 | 55,200 | Common Stock |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 150,000 | 150,000 | - | - | Performance Stock Units | |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 120,000 | 120,000 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Daniel Gordon Kirby | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 35,000 | 35,000 | - | - | Stock Options (Right to Buy) |